Longlight Completes Nearly Tens of Millions RMB in Angel Funding to Advance Integrated Sample Preparation Solutions

VCBeat learned at the earliest opportunity,Shenzhen Dayuan Chenguang Technology Co., Ltd.(abbreviation“Dayuan Chenguang”) announced.Nearly 10 Million Yuan in Angel RoundFinancing. This round of financing was led byYanghe CapitalLead Investor, Lighting GiantYHLO(Stock Code: 688575) co-investment. It is reported that the funds from this round will be used forOptimize Product Portfolio and Increase Market InvestmentandNew Factory and Team Building。

Dayuan Chenguang was founded in 2015, focusing onComprehensive Solutions for Diagnostic Research and Molecular Biology to Meet the Needs of Future Advanced Laboratories.The company was founded by university professors, overseas-returning technical experts, and senior specialists with decades of deep experience in the biotechnology market, accumulating extensive industry expertise in mechanical automation, biochemical reagents, and high-value consumables.

After years of technological research, development, and accumulation, the company has launchedChina’s First Focused Ultrasound Sample Processing System, the World’s Exclusive Flow-Through Vacuum Degassing System, and Laboratory ConsumablesandProtein Biologics...and other technologically advanced products, providing more sophisticated integrated laboratory solutions for research and clinical applications to support the ever-evolving field of biological research.

Focused ultrasound fragmentation is an essential step in whole-genome and tumor sample sequencing, widely accepted by sequencing users worldwide. In the past, this technology was long monopolized by foreign brands, leaving domestic customers with no bargaining power.

Dayuan Chenguang’s meticulously developed BoFU Focused Ultrasound Sample Processing System employs world-leading spherically focused ultrasound technology, breaking the monopoly held by overseas enterprises in this field and resolving critical industry bottlenecks. The BoFU Focused Ultrasound System precisely focuses high-frequency, short-wavelength acoustic waves onto samples, ensuring a highly controllable sample preparation process. This focused ultrasound technology efficiently utilizes acoustic energy by concentrating the vast majority of it within the sample region, thereby enhancing processing efficiency, minimizing heat generation, and preventing cross-contamination.

This product is widely applicable in various biological scenarios, including nucleic acid and chromatin shearing, fragmentation and preparation of nucleic acid samples for high-throughput sequencing systems, proteomics sample preparation, high-precision disruption and homogenization of biological tissues and cell cultures, and microbial lysis.

Dayuan Chenguang Focused Ultrasound Disruptor

Dayuan Chenguang develops biological laboratory instruments that rival imported brands in quality, leveraging its robust domestic R&D and production team. Meanwhile, through extensive localized manufacturing, the company keeps production costs at an industry-moderate level, thereby benefiting a broad base of scientific researchers.

Currently, Dayuan Chenguang has multiple products deployed in sequencing and pathogenic microorganism detection laboratories, serving numerous leading hospitals and sequencing service providers, with users distributed acrossPharmaceutical Manufacturers, Hospitals, Universities, Centers for Disease Control and Prevention (CDC), and Customsamong other customer segments, the product has been widely acclaimed.

Leveraging the successful experience and robust product quality of its domestic offerings, the overseas team has currently establishedWestern Europe, East Asia, South AmericaandMiddle EastSales channels in overseas countries and regions have recently been launched, exporting Chinese expertise. Meanwhile, the company is actively engaged in the research and development of various new products, providing users with comprehensive end-to-end solutions for sample processing, including innovative instruments, consumables, and reagents.

Regarding this round of financing,Kang Yan, Founder of Dayuan Chenguangstated: “We extend our gratitude to the investors for their recognition and support of Dayuan Chenguang. As national healthcare reform policies continue to deepen, the government has provided strong support for domestically produced medical devices and scientific research instruments, while the capital market has paid particular attention to the development of the in vitro diagnostics (IVD) industry. Dayuan Chenguang possesses substantial technical reserves, product expertise, and industry resources in comprehensive laboratory sample processing solutions. Leveraging our current first-mover advantage in products and the manufacturing strengths of Shenzhen, we aim to translate our deep insights into customer needs into globally leading technologies and products, benefiting more users in China and around the world.”

Fu Chao, Vice President of Yanghe Investment“As the saying goes, ‘A single flower does not make spring; a garden in full bloom does.’ The development and prosperity of a major industry require not only industry leaders to spearhead innovation but also the support and collaboration of ‘hidden champions’ across various niche segments. This holds true for the molecular diagnostics and molecular pathology sectors. The founding team of Dayuan Chenguang brings extensive industry experience. By entering the market with focused ultrasound—a product addressing an unmet essential need—they have achieved performance comparable to the only similar product available globally. Their offerings have garnered recognition and acclaim from numerous renowned end-users and representative enterprises in China. Additionally, their product pipeline includes other sample processing and analysis solutions. We are delighted to partner with distinctive and high-potential companies like Dayuan Chenguang to jointly drive industry advancement.”

Yao Yiyu, Investment Director at YHLO Biotech“It is stated that the efficacy of sample pretreatment directly impacts the performance and precision of subsequent molecular testing. Currently, most laboratories continue to employ decades-old techniques for biological sample processing, which fail to fully meet the growing demands for digitalized and trace-level detection. Starting with China’s first focused ultrasound sample processing system, Dayuan Chenguang has extensively deployed innovative products and expanded into related fields to comprehensively address users’ emerging pretreatment needs, demonstrating a profound understanding of industry development and exceptional product innovation capabilities. YHLO’s participation in this financing round reflects its confidence in the Dayuan Chenguang team, which boasts solid expertise and a global perspective. YHLO also looks forward to leveraging its industrial resources to help Dayuan Chenguang become a leading comprehensive solution platform in the field of sample pretreatment at an early stage, thereby injecting momentum into the growth of partners with shared aspirations.”

Founded in 2013, Yanghe Investment is a China-based industrial investment firm specializing in niche healthcare sectors. It focuses primarily on medical technologies, innovative medical devices, and healthcare services, with its portfolio concentrated in the early to mid-stage companies. Committed to long-term value creation, the firm identifies investment opportunities through in-depth research of specialized sub-sectors and empowers its portfolio companies, achieving its own growth by fostering the success of its investments.

Shenzhen YHLO Biotech Co., Ltd. was established in 2008 and is a well-known listed company on the STAR Market in China (Stock Code: 688575). As an innovative enterprise in the field of in vitro diagnostics (IVD), the company boasts domestically leading technologies and focuses on providing total solutions for clinical laboratories. Its core business involves the research and development, manufacturing, and sales of IVD instruments and supporting reagents, primarily based on chemiluminescence immunoassay (CLIA) technology. Upholding its mission to “Focus on Life and Health, Strive to Benefit Humanity through Technology,” the company remains committed to excellence, continuously delivering superior products and services to advance human health.